Upregulation of the oestrogen target gene SIX1 is associated with higher growth speed and decreased survival in HCV-positive women with hepatocellular carcinoma.
TGF-β
biologic aggressiveness
hepatocellular carcinoma
microRNA
sex
sineoculis homeobox homolog 1
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
15
04
2022
accepted:
07
07
2022
entrez:
24
10
2022
pubmed:
25
10
2022
medline:
25
10
2022
Statut:
epublish
Résumé
The male/female ratio of patients with hepatocellular carcinoma (HCC) is often unbalanced towards the male sex, indicating a sex predisposition for HCC development. A possible explanation may be attributed to different hormonal statuses, including the pro-inflammatory action of androgens in men and the protective effects of oestrogen against excessive inflammation in women. Although several studies have studied gene expression in patients with HCC, very few have attempted to identify features that could be distinctive between male and female patients. The present study aimed to identify distinctive signalling mechanisms between men and women that may be associated with HCC progression. The present study analysed a detailed microarray database that was obtained from the prospective study of 78 patients with HCC to study gene expression according to sex. In addition, the present study aimed to evaluate whether the differentially expressed genes were known oestrogen targets. Moreover, RNAs from the HCC cohort were evaluated for microRNA (miRNA/miR) expression, and a relationship between miRNA and gene expression according to sex was investigated. One gene, sineoculis homeobox homolog 1 (SIX1), which is known to be an oestrogen target gene, was revealed to be highly upregulated in hepatitis virus C (HCV)-positive female patients with HCC but not in HCV-positive male patients. In addition, SIX1 upregulation had a significant relationship with tumour growth speed (assessed as tumour doubling time in two CTs performed 6 weeks apart) and survival (P=0.009 and P=0.042, respectively) in female patients only. Furthermore, SIX1 upregulation was related with miR-421 and miR-9-5p only in male patients; however, in female patients, SIX1 upregulation had a direct relationship with miR-181b, miR-503-5p and miR-125b (miRNAs with potential oncogenic capacity), and an inverse correlation with miR139-5p, miR-26b, let7c-3p and let7c-5p (putatively oncosuppressive microRNAs). These data suggested a distinctive model for liver carcinogenesis in HCV-positive women, with downregulation of protective mechanisms against tumour progression and the activation of potential oncogenes, in relation to the oestrogen target gene SIX1. (IRB10/08_CE_UniRer; ClinicalTrials ID: NCT01657695).
Identifiants
pubmed: 36276500
doi: 10.3892/ol.2022.13515
pii: OL-24-05-13515
pmc: PMC9533365
doi:
Banques de données
ClinicalTrials.gov
['NCT01657695']
Types de publication
Journal Article
Langues
eng
Pagination
395Informations de copyright
Copyright: © Critelli et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Cell Physiol Biochem. 2016;39(2):453-66
pubmed: 27383203
Mol Endocrinol. 2013 Oct;27(10):1666-77
pubmed: 24002655
Cancer. 1988 Aug 1;62(3):611-5
pubmed: 2839286
J Cell Mol Med. 2012 Jan;16(1):160-73
pubmed: 21352471
Womens Health (Lond). 2008 Jan;4:41-50
pubmed: 19072450
PLoS One. 2012;7(9):e44624
pubmed: 22970270
Oncol Lett. 2019 May;17(5):4222-4228
pubmed: 30988804
Biochem Biophys Res Commun. 2015 Sep 4;464(4):982-987
pubmed: 26163260
Cancer Res. 2010 Dec 15;70(24):10371-80
pubmed: 21056993
Cell Death Dis. 2017 Aug 24;8(8):e3017
pubmed: 28837142
Science. 2007 Jul 6;317(5834):121-4
pubmed: 17615358
Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):88-94
pubmed: 31712271
Mol Cancer Res. 2016 Sep;14(9):849-58
pubmed: 27259717
Biochem Biophys Res Commun. 2015 Jul 31;463(3):315-21
pubmed: 26022123
Int J Clin Exp Pathol. 2014 May 15;7(6):3018-27
pubmed: 25031720
Hepatology. 2021 Jan;73 Suppl 1:4-13
pubmed: 32319693
Cancer Res. 2007 Apr 1;67(7):3036-42
pubmed: 17409410
Elife. 2015 Sep 24;4:
pubmed: 26402456
Gut. 2016 May;65(5):861-9
pubmed: 25666192
Adv Cancer Res. 2008;101:93-126
pubmed: 19055944
Oncol Lett. 2018 Mar;15(3):3395-3402
pubmed: 29467864
Cell Mol Immunol. 2021 Dec;18(12):2660-2672
pubmed: 34782761
Cancer Biol Ther. 2018 May 4;19(5):381-390
pubmed: 29333942
Diagn Pathol. 2012 Oct 05;7:135
pubmed: 23039327
Oncol Rep. 2017 Jan;37(1):563-570
pubmed: 27840964
Gastroenterology. 1989 Apr;96(4):1102-9
pubmed: 2925054
Adv Clin Exp Med. 2022 Jun;31(6):655-670
pubmed: 35438846
Clin Breast Cancer. 2018 Oct;18(5):e875-e882
pubmed: 29478945
Int J Cancer. 2015 Nov 1;137(9):2104-13
pubmed: 25951369
PLoS One. 2015 Jan 23;10(1):e0116774
pubmed: 25615624
Onco Targets Ther. 2016 Jun 15;9:3535-44
pubmed: 27366090
Oncol Lett. 2015 Apr;9(4):1971-1975
pubmed: 25789078
Eur J Pharmacol. 2019 Oct 15;861:172599
pubmed: 31404537
Oncogene. 2010 Mar 25;29(12):1787-97
pubmed: 20023698
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Clin Invest. 2009 Sep;119(9):2678-90
pubmed: 19726885
Endocr Relat Cancer. 2014 May 06;21(3):R165-82
pubmed: 24424503
Auris Nasus Larynx. 2021 Jun;48(3):487-495
pubmed: 33077306
Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12608-13
pubmed: 9770533
J Transl Med. 2014 Apr 08;12:93
pubmed: 24708807
Environ Health Perspect. 2011 Nov;119(11):1575-82
pubmed: 21810550
Int J Cancer. 2016 Mar 1;138(5):1067-75
pubmed: 26096807